Prof. Gilboas research interests center on developing immunological approaches to treat cancer. At Princeton University (1980) he worked alongside Richard Mulligan and a few others on the development of retroviral vectors for gene therapy. After moving to Memorial Sloan Kettering Cancer Center (MSKCC) in New York City (1986) Eli expanded his research interest to HIV/AIDS, focusing on the development of ways to render human CD4+ T cells genetically resistant to HIV infection dubbed “intracellular immunization”. At MSKCC he also developed a program in cancer immunotherapy, developing gene-modified autologous tumor vaccines (Connor et al., J. Exp. Med., 1993). It was at MSKCC where he also became interested in developing dendritic cell (DC)-based cancer vaccines, developing a novel approach to load DCs with tumor antigens by transfection with the corresponding mRNA. The goal of Elis current program is to develop a combination of clinically feasible and broadly applicable treatments to increase the susceptibility of disseminated tumor lesions to immune elimination.

Eli Gilboa is the Dodson Professor of Microbiology & Immunology, UM/Sylvester Comprehensive Cancer Center at the Miller School of Medicine, University of Miami. Eli received his Ph.D. in molecular biology at the Weizmann Institute, Rehovoth, Israel. He was Assistant Professor in the Department of Molecular Biology at Princeton University from 1980 to 1986 and served as an Associate Member of the Sloan Kettering Institute from 1986 to 1992. He also served as a Professor in the Department of Surgery, Duke University Medical School from 1992-2006.

Information about his publications can be found at: https://www.ncbi.nlm.nih.gov/pubmed?term=Gilboa+E&cmd=DetailsSearch

Keywords: retroviral vectors, gene therapy, HIV/AIDS gene therapy, anticancer immunity, cancer vaccines, aptamer